

## Human PIGF Sandwich ELISA Kit Datasheet

Please read it entirely before use

**Catalogue Number:** KE00173

**Size:** 5\*96T

**Sensitivity:** 16.8 pg/mL

**Range:** 125-8000 pg/mL

**Usage:** For the quantitative detection of human PIGF concentrations in serum, plasma, cell culture supernatant and urine.


This product is for research use only and not for use in human or animal therapeutic or diagnostic.

<b>Table of content</b>	<b>page</b>
1. Background .....	3
2. Principle .....	3
3. Required Materials .....	3
4. Kit Components and Storage .....	4
5. Safety Notes .....	4
6. Sample Collection and Storage .....	4
7. Regent Preparation .....	5
8. Assay Procedure Summary .....	6
9. Validation Data .....	7
9.1 Standard curve .....	7
9.2 Precision .....	8
9.3 Recovery .....	8
9.4 Sample values .....	8
9.5 Sensitivity .....	9
9.6 Linearity .....	9
10. References .....	9

## 1. Background

PLGF (placenta growth factor), also named as PGF, is an angiogenic factor which belongs to vascular endothelial growth factor (VEGF) family. The human PLGF gene is located on chromosome 14q14 and encodes 4 isoforms of PLGF. The protein is secreted as a glycosylated homodimer and PLGF-1 and -3 are diffusible isoforms whereas PLGF-2 and PLGF-4 have heparin binding domains. PLGF was originally identified in the placenta, where it regulates growth and differentiation of trophoblasts. It is also expressed in umbilical vein endothelial cells and other non-placental tissues, like the thyroid gland and developing lung tissue. PLGF has angiogenic properties, enhancing survival, growth and migration of endothelial cells in vitro, and promotes vessel formation in certain in-vivo models. Serum levels of PLGF and sFlt-1 (also known as soluble VEGF receptor-1) are altered in women with preeclampsia. PLGF is a potential biomarker for preeclampsia, a condition in which blood vessels in the placenta are too narrow, resulting in high blood pressure.

## 2. Principle



### Sandwich ELISA structure (Detection antibody labeled with biotin)

A capture antibody is pre-coated onto the bottom of wells which binds to analyte of interest. A detection antibody labeled with biotin also binds to the analyte. Streptavidin-HRP binds to the biotin. TMB acts as the HRP substrate and the solution color will change from colorless to blue. A stop solution containing sulfuric acid turns solution yellow. The color intensity is proportional to the quantity of bound protein which is measurable at 450 nm with the correction wavelength set at 630 nm.

## 3. Required Materials

- 3.1 A microplate reader capable of measuring absorbance at 450 nm with the correction wavelength set at 630 nm.
- 3.2 Calibrated, adjustable precision pipettes and disposable plastic tips. A manifold multi-channel pipette is recommended for large assays.
- 3.3 Plate washer: automated or manual.
- 3.4 Absorbent paper towels.
- 3.5 Glass or plastic tubes to prepare standard and sample dilutions.
- 3.6 Beakers and graduated cylinders.
- 3.7 Log-log or semi-log graph paper or computer and software for ELISA data analysis. A four-parameter logistic (4-PL) curve-fit is recommended.

## 4. Kit Components and Storage

Microplate - antibody coated 96-well microplate (8 well × 12 strips)	5 plates	<b>Unopened Kit:</b> Store at 2-8°C for 6 months or -20°C for 12 months.  <b>Opened Kit:</b> All reagents stored at 2-8°C for 7 days.  <b>Please use a new standard for each assay.</b>
Protein standard - 8000 pg/bottle; lyophilized	10 bottles	
Detection Antibody, biotinylated (100×) - 600 μ L/vial*	1 vial	
Streptavidin-horseradish peroxidase (HRP) (100×) - 600 μ L/vial*	1 vial	
Sample Diluent PT 1 - 150 mL/bottle. For human serum, cell culture supernatant and urine	1 bottle	
Sample Diluent PT 3 - 150 mL/bottle. For human plasma	1 bottle	
Detection Diluent - 150 mL/bottle	1 bottle	
Wash Buffer Concentrate (20×) - 150 mL/bottle	1 bottle	
Tetramethylbenzidine Substrate (TMB) - 60 mL/bottle	1 bottle	
Stop Solution - 60 mL/bottle	1 bottle	
Plate Cover Seals	15 pieces	

\* Centrifugation immediately before use

## 5. Safety Notes

- 5.1 Avoid any skin and eye contact with Stop Solution and TMB. In case of contact, wash thoroughly with water.
- 5.2 Do not use the kit after the expiration date.
- 5.3 Do not mix or substitute reagents or materials from other kit lots or other sources.
- 5.4 Be sure to wear protective equipment such as gloves, masks and goggles during the experiment.
- 5.5 When using an automated plate washer, adding a 30 second soak period following the addition of Wash Buffer to improve assay precision

## 6. Sample Collection and Storage

- 6.1 Serum: Allow blood samples to clot for 30 minutes, followed by centrifugation for 15 minutes at 1000×g. Clear serum can be assayed immediately or aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.
- 6.2 Plasma: Use EDTA, heparin, or citrate as an anticoagulant for plasma collection. Centrifuge for 15 minutes at 1000×g within 30 minutes of collection. The plasma can be assayed immediately or aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.
- 6.3 Cell Culture Supernatant: Remove particulates by centrifugation for 5 minutes at 500×g and assay immediately or aliquot and store samples at ≤ -20°C. Avoid repeated freeze-thaw cycles.
- 6.4 Urine: Collect urine samples and centrifuge for 20 minutes at 1000×g. Collect the aqueous layer, assay immediately or aliquot and store samples at ≤ -20°C. Avoid repeated freeze-thaw cycles.

## 7. Regent Preparation

**7.1 Wash Buffer (1X):** If crystals have formed in the concentrate, warm to room temperature and mix gently until the crystals have completely dissolved. Add 30 mL of Wash Buffer Concentrate(20X) to 570 mL deionized or distilled water to prepare 1X Wash Buffer.

**7.2 Detection Antibody (1X):** Dilute 100X Detection Antibody 1:100 using Detection Diluent prior to assay. Suggested 1:100 dilution: 10  $\mu$  L 100X Detection Antibody + 990  $\mu$  L Detection Diluent (Centrifuge the 100 X Detection Antibody solution for a few seconds prior to use).


**7.3 Streptavidin-HRP (1X):** Dilute 100X Streptavidin-HRP 1:100 using Detection Diluent prior to assay. Suggested 1:100 dilution: 10  $\mu$  L 100X Streptavidin-HRP + 990  $\mu$  L Detection Diluent (Centrifuge the 100X Streptavidin-HRP solution for a few seconds prior to use).

**7.4 Sample Dilution:** Different samples should be diluted with corresponding Sample Diluent, samples may require further dilution if the readout values are higher than the highest standard OD reading. Variations in sample collection, processing and storage may affect the results of the measurement.

Recommended Dilution for different sample types: 1:2 or 1:4 is recommended for human serum and plasma; 1:4 or 1:8 is recommended for cell culture supernatant; 1:2 or 1:4 is recommended for urine.

### 7.5 Standard Serial Dilution:

For human serum, cell culture supernatant and urine samples, add 1 mL Sample Diluent PT 1 in protein standard; For human plasma samples, add 1 mL Sample Diluent PT 3 in protein standard.



Add # $\mu$ L of Standard diluted in the previous step	—	500 $\mu$ L	500 $\mu$ L	500 $\mu$ L	500 $\mu$ L	500 $\mu$ L	500 $\mu$ L
# $\mu$ L of Sample Diluent PT 1 or PT 3	1000 $\mu$ L	500 $\mu$ L	500 $\mu$ L	500 $\mu$ L	500 $\mu$ L	500 $\mu$ L	500 $\mu$ L
	"sd7"	"sd6"	"sd5"	"sd4"	"sd3"	"sd2"	"sd1"

## 8. Assay Procedure Summary

Bring all reagents to room temperature before use (Detection antibody and Streptavidin-HRP can be used immediately). To avoid cross-contamination, change pipette tips between additions of each standard level, between sample additions, and between reagent additions. Also, use separate reservoirs for each reagent.

8.1 Take out the required number of microplate strips and return excess strips to the foil pouch containing the drying reagent pack and reseal; store at 4°C immediately. Microplate strips should be used in one week.

8.2 Preset the layout of the microplate, including control group, standard group and sample group, add 100 µL of each standard and sample to the appropriate wells. (Make sure sample addition is uninterrupted and completed within 5 to 10 minutes, it is recommended to assay all standards, controls, and samples in duplicate).

8.3 Seal plate with cover seal, pressing it firmly onto top of microwells. Incubate the plate for 2 hours at 37°C.

8.4 Wash

1) Gently remove the cover seal. Discard the liquid from wells by aspirating or decanting. Remove any residual solution by tapping the plate a few times on fresh paper towels.

2) Wash 4 times with 1X Wash Buffer, using at least 350-400 µL per well. Following the last wash, firmly tap plates on fresh towels 10 times to remove residual Wash Buffer. Avoid getting any towel fibers in the wells or wells drying out completely.

8.5 Add 100 µL of 1X Detection Antibody solution (refer to Reagent Preparation 7.2) to each well. Seal plate with cover seal and incubate for 1 hour at 37°C.

8.6 Repeat wash step in 8.4.

8.7 Add 100 µL of 1X Streptavidin-HRP solution (refer to Reagent Preparation 7.3) to each well. Seal plate with cover seal and incubate the plate for 40 minutes at 37°C.

8.8 Repeat wash step in 8.4.

8.9 Signal development: Add 100 µL of TMB substrate solution to each well, protected from light. Incubate for 15 to 20 minutes. Substrate Solution should remain colorless until added to the plate.

8.10 Quenching color development: Add 100 µL of Stop Solution to each well in the same order as addition of the TMB substrate. Mix by tapping the side of the plate gently. NB: Avoid skin and eye contact with the Stop solution.

8.11 Read results: Immediately after adding Stop solution read the absorbance on a microplate reader at a wavelength of 450 nm. If possible, perform a double wavelength readout (450 nm and 630 nm).


8.12 Data analysis: Calculate the average of the duplicate readings (OD value) for each standard and sample, and subtract the average of the zero standard absorbance. Construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis, use four-parameter logistic curve-fit (4-PL) analysis to do this. If the samples have been diluted, the OD readout from the standard curve must be multiplied by the dilution factor used.

Step	Reagent	Volume	Incubation	Wash	Notes
1	Standard and Samples	100 µL	120 min	4 times	Cover Wells incubate at 37°C
2	Diluent Antibody Solution	100 µL	60 min	4 times	Cover Wells incubate at 37°C
3	Diluent HRP Solution	100 µL	40 min	4 times	Cover Wells incubate at 37°C
4	TMB Substrate	100 µL	15-20 min	Do not wash	Incubate in the dark at 37°C
5	Stop Solution	100 µL	0 min	Do not wash	-
6	Read plate at 450 nm and 630 nm immediately after adding Stop solution. DO NOT exceed 5 minutes.				


## 9. Validation Data

### 9.1 Standard curve

These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.



(pg/mL)	O.D.	Average	Corrected
0	0.051 0.049	0.050	-
125	0.230 0.228	0.229	0.179
250	0.369 0.362	0.366	0.316
500	0.579 0.565	0.572	0.522
1000	0.873 0.880	0.877	0.827
2000	1.343 1.281	1.312	1.262
4000	1.817 1.793	1.805	1.755
8000	2.261 2.282	2.272	2.222



(pg/mL)	O.D.	Average	Corrected
0	0.042 0.045	0.044	-
125	0.225 0.224	0.225	0.181
250	0.385 0.383	0.384	0.340
500	0.620 0.614	0.617	0.573
1000	0.973 0.975	0.974	0.930
2000	1.398 1.420	1.409	1.365
4000	1.867 1.876	1.872	1.828
8000	2.371 2.359	2.365	2.321

## 9.2 Precision

**Intra-assay Precision** (Precision within an assay) Three samples of known concentration were tested 20 times on one plate to assess intra-assay precision.

**Inter-assay Precision** (Precision between assays) Three samples of known concentration were tested in 24 separate assays to assess inter-assay precision.

Intra-assay Precision					Inter-assay Precision				
Sample	n	Mean (pg/mL)	SD	CV%	Sample	n	Mean (pg/mL)	SD	CV%
1	20	4,631	272.8	5.9	1	24	4,095	307.0	7.5
2	20	1,009	62.7	6.2	2	24	959	54.1	5.6
3	20	238	14.2	5.9	3	24	230	12.9	5.6

## 9.3 Recovery

The recovery of human PIGF spiked to three different levels throughout the range of the assay in various matrices was evaluated.

Sample Type		Average% of Expected	Range (%)
Human plasma	1:2	82	70-101
	1:4	93	72-118
Human serum	1:2	82	72-97
	1:4	84	75-100
Cell culture supernatant	1:4	84	74-101
	1:8	100	91-110
Urine	1:2	91	85-98
	1:4	88	80-96

## 9.4 Sample values

Human serum and plasma samples from healthy volunteers were evaluated for human PIGF in this assay. No medical histories were available for the donors used in this study.

Sample Type	Mean of Detectable (pg/mL)	%Detectable	Range (pg/mL)
Human serum (n=16)	9.3	19	ND*-20
Human plasma (n=16)	28	100	24-33

ND\*=Non-detectable

### Cell culture supernatant

JAR human placental choriocarcinoma cells were grown in DMEM with 10% fetal bovine serum for 4 days. The measured value was 1,600 pg/mL.



## 9.5 Sensitivity

The minimum detectable dose of human PIGF is 16.8 pg/mL. This was determined by adding two standard deviations to the concentration corresponding to the mean O.D. of 20 zero standard replicates.

## 9.6 Linearity

To assess the linearity of the assay, The human serum, plasma and urine samples were spiked with high concentrations of human PIGF in various matrices and diluted with the appropriate **Sample Diluent** to produce samples with values within the dynamic range of the assay. The cell culture supernatant was diluted with the appropriate **Sample Diluent** to produce samples with values within the dynamic range of the assay.

		Human serum (Sample Diluent PT 1)	Human plasma (Sample Diluent PT 3)	Cell culture supernatant (Sample Diluent PT 1)	Urine (Sample Diluent PT 1)
1:2	Average% of Expected	97	92	100	95
	Range (%)	92-102	72-119	-	88-101
1:4	Average% of Expected	100	90	105	87
	Range (%)	98-102	72-108	102-107	81-92
1:8	Average% of Expected	92	91	112	81
	Range (%)	86-97	81-106	107-119	78-84
1:16	Average% of Expected	90	94	112	79
	Range (%)	78-103	81-110	100-127	77-82

## 10. References

1. Khalil A. et al. (2008) PLoS One. 23;3(7):e2766.
2. Dewerchin M. et al. (2012) Cold Spring Harb Perspect Med. 1;2(8).
3. Oura H. et .at. (2003) Blood.101(2):560-7.
4. Duhig KE. et al. (2019) Lancet. 393(10183):1807-1818.